First New Alzheimer’s Drug in Nearly Two Decades Is Approved by FDA

The first drug promising to slow the memory-robbing march of Alzheimer’s disease was approved by U.S. health regulators, a watershed after years of research and billions of dollars in investment.

The U.S. Food and Drug Administration said it approved the drug, which has the molecular name aducanumab and will be sold as Aduhelm, based on evidence it reduces a sticky substance in the brain called amyloid that is associated with Alzheimer’s.

The drug’s sale offers hope to millions of people dealing with Alzheimer’s and their caregivers, given the lack of good options...